Novartis Stock Price, News & Analysis (NYSE:NVS)

Novartis trades on the New York Stock Exchange (NYSE) under the ticker symbol "NVS."

Novartis announced an annual dividend on Thursday, January 31st. Stockholders of record on Tuesday, March 5th will be given a dividend of $2.8646 per share on Wednesday, March 13th. This represents a dividend yield of 3.27%. The ex-dividend date of this dividend is Monday, March 4th. This is a positive change from Novartis's previous annual dividend of $2.33. View Novartis' Dividend History.

Novartis AG (NYSE:NVS) released its earnings results on Thursday, October, 18th. The company reported $1.32 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.31 by $0.01. The company had revenue of $12.78 billion for the quarter, compared to analysts' expectations of $12.88 billion. Novartis had a return on equity of 18.55% and a net margin of 23.27%. The firm's revenue for the quarter was up 2.9% on a year-over-year basis. During the same period last year, the firm posted $1.29 earnings per share. View Novartis' Earnings History.

Novartis is scheduled to release their next quarterly earnings announcement on Tuesday, October 22nd 2019. View Earnings Estimates for Novartis.

12 analysts have issued twelve-month target prices for Novartis' shares. Their forecasts range from $79.16 to $105.00. On average, they anticipate Novartis' stock price to reach $91.94 in the next twelve months. This suggests a possible upside of 5.4% from the stock's current price. View Analyst Price Targets for Novartis.

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Novartis in the last year. There are currently 4 sell ratings, 1 hold rating, 6 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Novartis.

Media coverage about NVS stock has been trending very negative recently, according to InfoTrie Sentiment. InfoTrie scores the sentiment of press coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Novartis earned a media sentiment score of -3.2 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the company's share price in the next few days. View News Stories for Novartis.

Novartis saw a decline in short interest in the month of September. As of September 30th, there was short interest totalling 3,110,000 shares, a decline of 13.1% from the August 30th total of 3,580,000 shares. Based on an average trading volume of 2,000,000 shares, the short-interest ratio is presently 1.6 days. Approximately 0.1% of the shares of the company are short sold. View Novartis' Current Options Chain.

Some companies that are related to Novartis include Johnson & Johnson (JNJ), Roche Holdings AG Basel (RHHBY), Merck & Co., Inc. (MRK), Pfizer (PFE), Abbott Laboratories (ABT), Novo Nordisk A/S (NVO), Sanofi (SNY), AstraZeneca (AZN), AbbVie (ABBV), GlaxoSmithKline (GSK), Eli Lilly And Co (LLY), Bristol-Myers Squibb (BMY), Commonwealth Bank of Australia (CSLLY), Celgene (CELG) and Bayer (BAYRY).

Based on aggregate information from My MarketBeat watchlists, some companies that other Novartis investors own include Johnson & Johnson (JNJ), Pfizer (PFE), Intel (INTC), Walt Disney (DIS), AbbVie (ABBV), NVIDIA (NVDA), Cisco Systems (CSCO), AT&T (T), Gilead Sciences (GILD) and Merck & Co., Inc. (MRK).

Novartis' stock is owned by a number of of institutional and retail investors. Top institutional investors include Manning & Napier Group LLC (0.11%), Bristol John W & Co. Inc. NY (0.03%), Douglas Lane & Associates LLC (0.01%), Country Trust Bank (0.01%), Gofen & Glossberg LLC IL (0.01%) and Confluence Investment Management LLC (0.01%).

NVS stock was sold by a variety of institutional investors in the last quarter, including Thomasville National Bank, Manning & Napier Group LLC, Scout Investments Inc., Crossmark Global Holdings Inc., Country Trust Bank, Park National Corp OH, Stonebridge Capital Management Inc. and Measured Wealth Private Client Group LLC.

NVS stock was acquired by a variety of institutional investors in the last quarter, including Ferguson Wellman Capital Management Inc., CIBC Private Wealth Group LLC, Confluence Investment Management LLC, Bristol John W & Co. Inc. NY, Fox Run Management L.L.C., Clarus Wealth Advisors, Pacer Advisors Inc. and Grassi Investment Management.

Shares of NVS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of NVS stock can currently be purchased for approximately $87.25.

Novartis has a market capitalization of $199.96 billion and generates $51.90 billion in revenue each year. The company earns $12.61 billion in net income (profit) each year or $5.09 on an earnings per share basis. Novartis employs 125,161 workers across the globe.View Additional Information About Novartis.

The official website for Novartis is http://www.novartis.com/.

Novartis' mailing address is LICHTSTRASSE 35, BASEL V8, CH 4056. The company can be reached via phone at 011-41-61-324-1111 or via email at [email protected]